Combination treatment for advanced small cell lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a combination of two newer drugs (sacituzumab tirumotecan and anlotinib) for people with extensive-stage small cell lung cancer that has progressed after one prior treatment. The goal is to see if this combination can shrink tumors and help patients live longer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have extensive-stage small cell lung cancer (cancer that has spread beyond the lungs)
- You have had only one prior treatment, which included immunotherapy combined with chemotherapy
- You have at least one tumor that can be measured and has not been previously treated with radiation
- You are in good enough health to carry out daily activities (ECOG 0 or 1)
- You have adequate organ function, including blood counts, liver and kidney function
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two immunotherapy drugs (sintilimab and tafolecimab) plus standard chemotherapy as a first treatment for extensive-stage small cell lung cancer. The goal is to see if adding these drugs helps people live longer and have better outcomes.
This trial tests a combination of three drugs (benmelstobart, anlotinib, and chemotherapy) for people with extensive-stage small cell lung cancer who haven't had treatment yet. The goal is to see if this combination can shrink tumors and help patients live longer.
This trial tests a new combination of two drugs for people with extensive-stage small cell lung cancer that has progressed after initial treatment. The goal is to see if this combination can help control the cancer.
This trial tests two immunotherapy drugs (sacituzumab govitecan with atezolizumab or durvalumab) as ongoing treatment to keep extensive-stage small cell lung cancer from progressing. It is for people who have already completed initial chemotherapy and immunotherapy without their cancer getting worse.
This study tests a new combination of two drugs (sacituzumab tirumotecan and another drug) for people with advanced esophageal cancer. The goal is to see if the combination can shrink tumors or slow the cancer's growth.
This trial tests a combination of two drugs for advanced esophageal cancer that has grown despite earlier treatment. The goal is to see if this combination can help shrink tumors and slow the disease.
Hear when a new Small Cell Lung Cancer Extensive Stage trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.